– Participate in panel presentations on a variety of issues affecting
the industry –
TORONTO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/FSDDF?src=hash" target="_blank"gt;#FSDDFlt;/agt;–FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the
“Company”), announced today that Dr. Raza Bokhari, Co-Chairman and Chief
Executive Officer of FSD Pharma will participate in the Arcview Investor
Forum being held April 23-25, 2019, in Vancouver. The event will feature
leading public and private companies and thought leaders who are shaping
the future of the industry.
Dr. Bokhari will be the keynote speaker and participate in panels
discussing issues affecting the future of the industry, including
regulatory environment, financing and consumer trends. Dr. Sara May, the
recently appointed president of FV Pharma, will participate in a panel
about investing in plant genetics. The forum is by invitation only.
Details of the forum are as follows:
| Event: | ArcView Investor Forum | ||
| Date: | April 23 – 24, 2019 | ||
| Location: | The Westin Bayshore Vancouver, Canada |
About FSD Pharma
FSD Pharma is focused on the development of the highest quality indoor
grown, pharmaceutical grade cannabis and on the research and development
of novel cannabinoid-based treatments for several central nervous system
disorders, including chronic pain, fibromyalgia and irritable bowel
syndrome. The Company has 25,000 square feet available for production at
its Ontario facility with an additional 220,000 square feet currently in
development.
FSD facilities sit on 72 acres of land with 40 acres primed for
development and an expansion capability of up to 3,896,000 square feet.
FSD’s wholly-owned subsidiary, FV Pharma, is a licensed producer under
the Cannabis Act and Regulations, having received its cultivation
license on October 13, 2017. FV Pharma’s vision is to transform its
current headquarters in a Kraft plant in Cobourg, Ontario into the
largest hydroponic indoor grow facility in the world. FV Pharma intends
to cover all aspects of this exciting new industry, including
cultivation, legal, processing, manufacturing, extracts and research and
development. For additional information on the company, please visit our
website at www.fsdpharma.com.
About the Arcview Group
Founded in 2010, The Arcview Group is responsible for a number of
groundbreaking ventures in the cannabis industry. The Arcview Investor
Network has helped more than 1200 investors place $200 million+ behind
190 companies. Arcview Market Research has published over 20 reports
analyzing and forecasting the rapidly evolving cannabis space. Arcview’s
flagship annual report, “The State of Legal Marijuana Markets” has
become the industry standard for market analysis and data in the sector.
In 2015 Arcview became a partner in Canopy, the first seed-stage
mentor-driven business accelerator. Arcview is also co-founder of
Cannasure Insurance Services, the leading provider of business insurance
to the cannabis industry. Forbes Magazine recently named Arcview among
the top 5 financial firms in the cannabis sector. Learn more at arcviewgroup.com.
Forward-Looking Information
Certain statements contained in this press release constitute
forward-looking information. These statements relate to future
events or future performance. The use of any of the words “could”,
“intend”, “expect”, “believe”, “will”, “projected”, “estimated” and
similar expressions and statements relating to matters that are not
historical facts are intended to identify forward-looking information
and are based on FSD Pharma’s current belief or assumptions as to the
outcome and timing of such future events. Actual future results may
differ materially. Actual results and developments may differ materially
from those contemplated by these. The forward-looking information
contained in this press release is made as of the date hereof, and FSD
Pharma is not obligated to update or revise any forward-looking
information, whether as a result of new information, future events or
otherwise, except as required by applicable securities laws. Because of
the risks, uncertainties and assumptions contained herein, investors
should not place undue reliance on forward looking-information. The
foregoing statements expressly qualify any forward-looking information
contained herein.
Contacts
Investor Relations: Sandra Huard, Email: ir@fsdpharma.com,
Tel.: (647) 864-7969
Media Relations: Nic Johnson, Email: nic.johnson@russopartnersllc.com,
Tel.: (212) 845-4242